KR20220071185A - 암포테리신 b의 하이브리드 아미드 유도체 - Google Patents

암포테리신 b의 하이브리드 아미드 유도체 Download PDF

Info

Publication number
KR20220071185A
KR20220071185A KR1020227007294A KR20227007294A KR20220071185A KR 20220071185 A KR20220071185 A KR 20220071185A KR 1020227007294 A KR1020227007294 A KR 1020227007294A KR 20227007294 A KR20227007294 A KR 20227007294A KR 20220071185 A KR20220071185 A KR 20220071185A
Authority
KR
South Korea
Prior art keywords
unsubstituted
substituted
alkyl
compound
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227007294A
Other languages
English (en)
Korean (ko)
Inventor
마틴 디. 버크
아룬 마지
지아바오 장
수 얀
용 니안
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20220071185A publication Critical patent/KR20220071185A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227007294A 2019-08-08 2020-08-10 암포테리신 b의 하이브리드 아미드 유도체 Pending KR20220071185A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962884464P 2019-08-08 2019-08-08
US62/884,464 2019-08-08
US201962951753P 2019-12-20 2019-12-20
US62/951,753 2019-12-20
PCT/US2020/045566 WO2021026520A1 (en) 2019-08-08 2020-08-10 Hybrid amide derivatives of amphotericin b

Publications (1)

Publication Number Publication Date
KR20220071185A true KR20220071185A (ko) 2022-05-31

Family

ID=74503735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227007294A Pending KR20220071185A (ko) 2019-08-08 2020-08-10 암포테리신 b의 하이브리드 아미드 유도체

Country Status (12)

Country Link
US (1) US20230016424A1 (https=)
EP (1) EP4009985A4 (https=)
JP (1) JP7636004B2 (https=)
KR (1) KR20220071185A (https=)
CN (1) CN114555094A (https=)
AU (1) AU2020325163B2 (https=)
BR (1) BR112022001866A2 (https=)
CA (1) CA3149916A1 (https=)
CL (1) CL2022000319A1 (https=)
IL (1) IL290289B2 (https=)
MX (1) MX2022001678A (https=)
WO (1) WO2021026520A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US20230357303A1 (en) * 2020-08-10 2023-11-09 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin b
CN115536716B (zh) * 2021-06-29 2025-08-08 中国科学院上海药物研究所 两性霉素b半合成衍生物及其制备方法和用途
TW202519239A (zh) * 2023-07-19 2025-05-16 美國伊利諾大學理事會 利用遺失蛋白質（ｍｉｓｓｉｎｇ ｐｒｏｔｅｉｎｓ）之小分子模擬物恢復生理機能
GB202406857D0 (en) * 2024-05-15 2024-06-26 Univ Manchester Polyenes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122086B1 (en) * 1979-04-09 1982-06-30 Politechnika Gdanska Process for preparing amides of antibiotics from the group of polyene macrolides and their derivativesvykh makrolidov i ikh proizvodnykh
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
US6664241B2 (en) * 2000-05-31 2003-12-16 Micrologix Biotech Inc. Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
MX365184B (es) * 2010-12-21 2019-05-21 Centro De Investig Y De Estudios Avanzados Del I P N Nuevos compuestos analogos de la anfotericina y composiciones farmaceuticas que los contienen.
KR20150027217A (ko) * 2012-06-15 2015-03-11 블러트 에스.에이. 항진균성 항생 암포테리신 b의 n-치환된 제2 세대 유도체, 및 이의 제조 및 응용 방법
WO2015164289A1 (en) 2014-04-21 2015-10-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
JP6543272B2 (ja) * 2014-05-16 2019-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 低減された毒性を有するアンホテリシンｂ誘導体
TWI702223B (zh) 2014-06-12 2020-08-21 日商塩野義製藥股份有限公司 多烯巨環內酯衍生物
AU2016205187B2 (en) 2015-01-08 2020-02-27 The Board Of Trustees Of The University Of Illinois Concise synthesis of urea derivatives of amphotericin B
CA3021061C (en) * 2015-04-15 2023-10-24 Martin D. Burke Derivatives of amphotericin b
US10322187B2 (en) * 2015-08-10 2019-06-18 Lehigh University Reduced toxicity molecular conjugates of anti-fungal agents
RU2688658C1 (ru) * 2018-04-10 2019-05-22 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Противогрибковый полусинтетический полиеновый антибиотик, его водорастворимые соли и фармацевтические композиции на их основе

Also Published As

Publication number Publication date
JP2022543420A (ja) 2022-10-12
AU2020325163B2 (en) 2026-04-23
EP4009985A4 (en) 2023-09-06
IL290289A (en) 2022-04-01
CL2022000319A1 (es) 2022-10-21
CA3149916A1 (en) 2021-02-11
IL290289B1 (en) 2025-11-01
US20230016424A1 (en) 2023-01-19
WO2021026520A1 (en) 2021-02-11
IL290289B2 (en) 2026-03-01
MX2022001678A (es) 2022-05-18
AU2020325163A1 (en) 2022-03-03
EP4009985A1 (en) 2022-06-15
BR112022001866A2 (pt) 2022-03-29
CN114555094A (zh) 2022-05-27
JP7636004B2 (ja) 2025-02-26

Similar Documents

Publication Publication Date Title
KR20220071185A (ko) 암포테리신 b의 하이브리드 아미드 유도체
EP3487856B1 (de) Substituierte diazaheterobicyclische verbindungen und ihre verwendung
EP3283171B1 (en) Derivatives of amphotericin b
US20190135854A1 (en) Oxysterols and methods of use thereof
AU2017311047A1 (en) TLR7/8 antagonists and uses thereof
EP3700903A1 (de) Substituierte imidazopyridinamide und ihre verwendung
WO2014165676A1 (en) Amphotericin b derivative with reduced toxicity
US11198705B2 (en) Hybrid Amphotericin B derivatives with reduced toxicity
KR20220058547A (ko) 감소된 독성을 갖는 하이브리드 암포테리신 b 유도체
WO2020216669A1 (de) Phenylsubstituierte imidazopyridinamide und ihre verwendung
JP7656359B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
KR20250052366A (ko) Dsgpeg2k 미셀에서 암포테리신 b 하이브리드 아미드 유도체의 제형
CA3033240C (en) Tlr7/8 antagonists and uses thereof
HK1244248B (en) Derivatives of amphotericin b

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000